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ABSTRACT
Anti-tuberculosis drug regimens are efﬁcacious, but drug
intolerance can be severe and may impact on treatment
completion rates. The Enhanced Tuberculosis Surveillance
(ETS) system is a case register of all new notiﬁcations of
tuberculosis in England, Wales and Northern Ireland. We
conducted a cohort study to estimate the incidence of,
and risk factors for, drug intolerance reported through
ETS between 2001 and 2010 and to assess its
relationship with treatment non-completion. Reports of
drug intolerance were found for 868/67 547 (1.28%)
patients in the cohort, and important risk factors were
female sex, older age, later case report year and white
ethnicity. Drug intolerance was associated with an
approximate ﬁvefold increased odds of treatment non-
completion (p<0.001). These results highlight the need
for better-tolerated drug regimens and close case
management of patients at risk of drug intolerance to
improve treatment completion rates and contribute to
more effective disease control.
INTRODUCTION
Ensuring that people with tuberculosis (TB) suc-
cessfully complete their treatment is not only life
saving for the individual but also reduces the
number of infectious cases in the community,
leading to population disease control.1 One of the
barriers to successful completion of therapy is poor
adherence, which can result from a range of
anti-TB drug intolerance conditions such as gastro-
intestinal upset, rash and hepatotoxicity.2 The inci-
dence of anti-TB drug intolerance among the
population of TB patients in the UK has not been
estimated previously, and there are little reported
data for its effect on the overall outcome of
treatment.
In this paper, we present the incidence of, and
clinical and demographic risk factors associated
with, reported anti-TB drug intolerance in England,
Wales and Northern Ireland and determine the
relationship of reported drug intolerance with non-
completion of TB treatment.
METHODS
This was an analysis of the cohort of patients diag-
nosed with active TB and reported through the
Enhanced Tuberculosis Surveillance (ETS) system
between 2001 and 2010.
The incidence of reported cases of anti-TB drug
intolerance was estimated by combining reports
made through a categorical ﬁeld for patients still on
treatment at follow-up with those made through
free text comments for patients with any treatment
outcome. A wide set of search terms was used to
query these comments, including phrases referring
to speciﬁc recognised adverse events and names of
anti-TB drugs.
Drug intolerance in the cohort was described in
terms of reported condition and the drugs speciﬁed
as the cause. Single and multivariable logistic
regression analyses were used to identify risk
factors for development of drug intolerance in the
cohort.
The effect of drug intolerance on treatment non-
completion was also investigated through logistic
regression analysis. The outcome was non-
completion of treatment, which included patients
whose ﬁnal outcomes were still on treatment, died
during treatment, lost to follow-up, stopped treatment
and those who had not ﬁnished treatment for an
unknown reason. A multivariable model was built to
determine the relationship after adjusting for other
signiﬁcant covariates in the data.
All analyses were conducted using Stata V.12,
Stata Corporation, Texas, USA.
RESULTS
The cohort comprised 67 547 cases of TB reported
in England, Wales and Northern Ireland through
ETS between 2001 and 2010. This excluded 1067
cases whose diagnosis was made postmortem and
6984 with a ﬁnal treatment outcome missing, as
these patients would not have had intolerance
recorded, and 390 with MDR TB, as the second-
line treatments used to treat MDR TB are known
to cause a higher frequency of adverse events.
A total of 866 reports of drug intolerance were
identiﬁed, representing 1.28% of TB notiﬁcations.
Of these, 265 were identiﬁed through the speciﬁed
treatment outcome ﬁeld and a further 601 from
the keyword search of the free text comments ﬁeld.
The nature of the intolerance condition was
reported in 233 of the 866 records of drug intoler-
ance, and the drug thought to be responsible in
268 records. Hepatotoxicity was the most common
disorder (160, 18.5% records) and pyrazinamide
the most frequently reported drug (135, 15.6%
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records). Factors found to be signiﬁcantly associated with
reporting of adverse drug reactions at multivariable analysis
were older age, female sex, white ethnicity and case report year
(table 1).
A total of 10 216 of the 66 843 patients whose treatment
regimen was not planned to extend beyond the follow-up
period had not completed treatment at follow-up. There were
844 cases of drug intolerance in this cohort, of which 450
(53.3%) did not complete treatment, compared with 9766
(14.8%) of the 65 999 patients with no reported drug
intolerance.
Logistic regression analysis gave an unadjusted OR of 6.58
(95% CI 5.73 to 7.54, p<0.001) for the effect of drug intoler-
ance on treatment non-completion. Following adjustment for
other signiﬁcant covariates (age, sex, case report year, whether
the patient was born in the UK, resistance to isoniazid, pyrazina-
mide or ethambutol), the adjusted OR was 4.95 (95% CI 4.05
to 6.05, p<0.001).
Table 1 Single and multivariable analysis of association between exposure variables and anti-tuberculosis drug intolerance
Risk factor
Drug intolerance Single variable analysis Multivariable analysis
Yes
(N=866)
No
(N=66 681) OR (95% CI) p Value Adjusted OR (95% CI) p Value
Age (years)
0–14 15 3710 0.46 (0.27 to 0.77) 0.003 0.41 (0.24 to 0.70) 0.001
15–44 362 40 918 1 1
45–64 234 12 837 2.06 (1.75 to 2.44) <0.001 1.77 (1.49 to 2.11) <0.001
65+ 255 9211 3.13 (2.66 to 3.68) <0.001 2.31 (1.93 to 2.78) <0.001
Sex
Male 318 36 700 1 1
Female 543 29 825 2.10 (1.83 to 2.42) <0.001 2.24 (1.95 to 2.59) <0.001
Year
2001 58 4914 1 <0.001* 1
2002 66 5545 1.00 (0.71 to 1.43) 1.08 (0.76 to 1.55) 0.66
2003 38 5712 0.56 (0.37 to 0.85) 0.61 (0.40 to 0.93) 0.022
2004 56 6048 0.78 (0.54 to 1.13) 0.86 (0.59 to 1.25) 0.43
2005 64 6780 0.80 (0.56 to 1.14) 0.96 (0.67 to 1.37) 0.81
2006 78 7265 0.91 (0.64 to 1.28) 1.02 (0.72 to 1.45) 0.91
2007 84 7435 0.96 (0.68 to 1.34) 1.12 (0.80 to 1.59) 0.51
2008 129 7638 1.43 (1.05 to 1.96) 1.69 (1.23 to 2.33) 0.001
2009 158 7981 1.68 (1.23 to 2.27) 1.91 (1.40 to 2.61) <0.001
2010 135 7363 1.55 (1.14 to 2.12) 1.80 (1.32 to 2.48) <0.001
Ethnic group
White 341 13 845 2.19 (1.87 to 2.56) <0.001 1.97 (1.67 to 2.33) <0.001
Black Caribbean 9 1633 0.49 (0.25 to 0.95) 0.036 0.55 (0.28 to 1.07)
Black African 109 14 826 0.65 (0.52 to 0.82) <0.001 0.80 (0.64 to 1.01) 0.078
Indian/Pakistani/Bangladeshi 298 26 520 1 1 0.058
Other 82 7944 0.92 (0.72 to 1.18) 0.50 1.04 (0.79 to 1.52) 0.59
UK-born
No 469 44 917 1
Yes 320 16 968 1.81 (1.57 to 2.09) <0.001
Site of disease
Pulmonary 395 30 612 1
Extrapulmonary 394 29 857 1.02 (0.89 to 1.18) 0.75
Both 73 5995 0.94 (0.73 to 1.21) 0.65
Neither recorded 4 217 1.43 (0.53 to 3.86) 0.48
Previous diagnosis
No 676 50 609 1
Yes 85 4540 1.40 (1.12 to 1.76) 0.004
Previous treatment
No 16 426 1
Yes 36 2347 0.41 (0.22 to 0.74) 0.003
Resistance to INH, PZA or EMB
No 450 35 235 1
Yes 35 2354 1.16 (0.82 to 1.65) 0.39
Sputum smear positive
No 212 16 382 1.19 (0.96 to 1.47) 0.11
Yes 147 13 505 1
*p trend.
EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide.
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DISCUSSION
This is the ﬁrst analysis of anti-TB drug intolerance and its rela-
tionship to non-completion of treatment in England, Wales and
Northern Ireland derived from the ETS system, a whole popula-
tion case register of TB patients.
Intolerance to anti-TB drugs was reported in 1.28% of notiﬁ-
cations. This ﬁgure includes records in which drug intolerance
had been indicated through free text comments, a threefold
increase in reports compared with those made using the dedi-
cated drug intolerance ﬁeld only. This is partly because the drug
intolerance ﬁeld can only be completed for patients who are still
on treatment at follow-up, and therefore omits those who
experienced adverse events during their treatment but who, for
example, completed treatment or were lost to follow-up.
Previous attempts to measure the incidence of drug intoler-
ance in other settings have produced higher estimates, with
8.6% patients affected in a smaller single-centre cohort2 and
30% in a population-based study involving regular standardised
collection of information regarding patients’ tolerance to the TB
medications.3 This indicates that the number reports of intoler-
ance to anti-TB drugs ascertained here are an underestimate of
the true incidence of adverse events. A limitation of this method
for identifying cases of drug intolerance that has contributed to
this is the lack of standardisation in data entry: Drug intolerance
information is not actively sought on ETS, there is no agreed
system for grading side effects and completion of comments
relies on retrospective recall by the case manager. It is therefore
probable that only the most severe adverse events, or those that
resulted in a change of treatment regimen, would prompt a case
manager to comment.
Hepatotoxicity was the predominant reported adverse event
caused by anti-TB drugs, and pyrazinamide was most frequently
suggested as the cause. These results are consistent with previ-
ous understanding,2 3 although details of conditions and drugs
were only available for approximately 30% of the reports of
drug intolerance. Important risk factors associated with drug
intolerance in this cohort were female sex, older age, later case
report year and white ethnicity. Other studies2 have found
similar relationships with sex and age, but it is probable that the
association with year reﬂects a change in the way that the com-
ments section has been used over time, rather than a real
increase in incidence. There may also be residual confounding
for factors that could not be controlled for in this study; notably
HIV status,2 which is not included in TB surveillance data in the
UK, and alcoholism, homelessness and drug use, which have
only been collected in ETS since 2009.
This study provided evidence that drug intolerance is asso-
ciated with an approximate ﬁvefold increased odds of treat-
ment non-completion. Although this is a logical association,
few attempts have previously been made to quantify it.
Adverse events were associated with a twofold higher rate of
unsuccessful treatment outcomes at 6 months in one study, but
this was a smaller analysis of patients at a single tertiary care
hospital.4
The crude relationship between drug intolerance and non-
completion of treatment was partially confounded by a number
of covariates that were included in the adjusted analysis, but,
again, there may have been residual confounding from unmeas-
ured covariates such as alcohol dependence, homelessness and
refugee status.5 The precision of our estimate of the effect of
drug intolerance on treatment failure may also have been impli-
cated by the likely underestimation of intolerance in the cohort
and by the restriction of the categorical drug intolerance option
on ETS to patients who are still on treatment at follow-up. This
restriction would tend to increase the effect on treatment non-
completion, although these reports made up a minority of the
overall number of reports of drug intolerance that were
ascertained.
The observed relationship between drug intolerance and treat-
ment non-completion has consequences for the management of
TB in patients with these symptoms. Such patients are more
likely to have their treatment extended due to changes in drug
regimens, are less likely to comply with treatment and are more
likely to become lost to follow-up. As a result, they are prone to
have longer disease duration, increasing their risk of death and
the potential for the disease to spread. This highlights the
importance of consultation with expert respiratory physicians
where possible regarding management of patients with symp-
toms of drug intolerance and the crucial role of close case man-
agement by respiratory nurse specialists in the community so
that issues can be detected early and dealt with accordingly. A
more systematic way of recording instances of drug intolerance
and classifying their severity would aid this, for example, by
extending the dedicated drug intolerance ﬁeld so that it can be
completed for any case in ETS.
In conclusion, we provide evidence that intolerance to
anti-TB drugs is signiﬁcantly associated with failure to complete
TB treatment regimens in the UK. A more accurate picture of
the burden of these adverse events and the extent of the impact
on treatment completion could be obtained through prospective
systematic recording on ETS. Development of new, less toxic
treatments should be given a high priority in order to reduce
patient suffering, improve treatment completion rates and con-
tribute to control of the disease.
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